Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes

CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- Prime Medicine, Inc. (Nasdaq: PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties. "I am happy we have reached an amicable settlement with Myeloid. We believe resolving this dispute is in the best interest of our shareholders and allows each company to pursue its goals of developing differentiated ...